A phase 2 study from Spiera et al. found that patients with glucocorticoid-dependent PMR taking the antibody-drug conjugate ABBV-154 had a longer time to flare compared with those taking placebo, supporting further investigation.
Latest News
JAK Inhibitors 101
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
New Diagnostic Code R76.81 Can Be Used to Identify Those at Risk of Developing RA
New ICD-10-CM code R76.81 can now be used for patients who have abnormal rheumatoid arthritis (RA)-related autoantibodies—but not RA—to improve early disease risk identification, preventive care and research.
2026 Medicare Physician Fee Schedule Proposed Rule Released
The proposed rule includes several proposals related to Medicare physician payment and the Quality Payment Program. Read more about the provisions the ACR will address during the comment period.
Connect with Your Lawmakers During the August Recess
August offers an opportunity to engage with your elected officials in your state or district. Lawmakers will be considering appropriations bills when they return in September—help make sure the needs of the rheumatology community are top of mind.
Transform Your Rheumatology Practice at the 2025 Practice Innovation Summit
The inaugural event, to be held before ACR Convergence, will offer actionable strategies and expert insights to build a smarter, stronger and more financially sustainable practice in today’s rapidly evolving healthcare landscape.
